These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 26791369)

  • 1. Point-Counterpoint: The FDA Has a Role in Regulation of Laboratory-Developed Tests.
    Caliendo AM; Hanson KE
    J Clin Microbiol; 2016 Apr; 54(4):829-33. PubMed ID: 26791369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintaining Life-saving Testing for Patients With Infectious Diseases: Infectious Diseases Society of America, American Society for Microbiology, and Pan American Society for Clinical Virology Recommendations on the Regulation of Laboratory-developed Tests.
    Caliendo AM; Couturier MR; Ginocchio CC; Hanson KE; Miller MB; Walker KE; Frank GM;
    Clin Infect Dis; 2016 Jul; 63(2):151-4. PubMed ID: 27118790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
    Tazawa Y
    Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory-Developed Tests: A Legislative and Regulatory Review.
    Genzen JR; Mohlman JS; Lynch JL; Squires MW; Weiss RL
    Clin Chem; 2017 Oct; 63(10):1575-1584. PubMed ID: 28687634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Laboratory-Developed Tests and FDA-Approved Assays for BRAF, EGFR, and KRAS Testing.
    Kim AS; Bartley AN; Bridge JA; Kamel-Reid S; Lazar AJ; Lindeman NI; Long TA; Merker JD; Rai AJ; Rimm DL; Rothberg PG; Vasalos P; Moncur JT
    JAMA Oncol; 2018 Jun; 4(6):838-841. PubMed ID: 29242895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. College of american pathologists proposal for the oversight of laboratory-developed tests.
    Vance GH
    Arch Pathol Lab Med; 2011 Nov; 135(11):1432-5. PubMed ID: 22032569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Facing the Inevitable: Being Prepared for Regulatory Requirements for Laboratory Developed Tests.
    D'Angelo R; Weiss R; Wolfe D; Chinnam R; Murat A; Gluesing J; Somers T
    Am J Clin Pathol; 2018 Apr; 149(6):484-498. PubMed ID: 29659675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of Laboratory-Developed Tests.
    Genzen JR
    Am J Clin Pathol; 2019 Jul; 152(2):122-131. PubMed ID: 31242284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LDTs and the FDA: The saga continues.
    Longwell A
    MLO Med Lab Obs; 2017 Apr; 49(4):40, 43. PubMed ID: 29979012
    [No Abstract]   [Full Text] [Related]  

  • 10. Temporary Regulatory Deviations and the Coronavirus Disease 2019 (COVID-19) PCR Labeling Update Study Indicate What Laboratory-Developed Test Regulation by the US Food and Drug Administration (FDA) Could Look Like.
    Marble HD; Bard AZ; Mizrachi MM; Lennerz JK
    J Mol Diagn; 2021 Oct; 23(10):1207-1217. PubMed ID: 34538703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding the Food and Drug Administration's Jurisdiction Over Laboratory-Developed Tests and Divisions Between Food, Drug, and Cosmetic Act-Regulated and Clinical Laboratory Improvement Amendments of 1988-Regulated Activities.
    Thompson BM; Scott BI; Boiani JA
    Clin Lab Med; 2016 Sep; 36(3):575-85. PubMed ID: 27514469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Laboratory-Developed Tests: Design of a Regulatory Strategy in Compliance with the International State-of-the-Art and the Regulation (EU) 2017/746 (EU IVDR [In Vitro Diagnostic Medical Device Regulation]).
    Spitzenberger F; Patel J; Gebuhr I; Kruttwig K; Safi A; Meisel C
    Ther Innov Regul Sci; 2022 Jan; 56(1):47-64. PubMed ID: 34291407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Test verification and validation for molecular diagnostic assays.
    Halling KC; Schrijver I; Persons DL
    Arch Pathol Lab Med; 2012 Jan; 136(1):11-3. PubMed ID: 22208481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation of Laboratory-Developed Tests in Preventive Oncology: Emerging Needs and Opportunities.
    Offit K; Sharkey CM; Green D; Wu X; Trottier M; Hamilton JG; Walsh MF; Dandiker S; Belhadj S; Lipkin SM; Sugrañes TA; Caggana M; Stadler ZK
    J Clin Oncol; 2023 Jan; 41(1):11-21. PubMed ID: 35944238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011.
    Rathi VK; Krumholz HM; Masoudi FA; Ross JS
    JAMA; 2015 Aug; 314(6):604-12. PubMed ID: 26262798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New FDA draft guidance on premarket submissions.
    Donawa ME
    Med Device Technol; 1999 Oct; 10(8):12-4. PubMed ID: 10724773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid diagnostic tests for infectious diseases in the emergency department.
    Bouzid D; Zanella MC; Kerneis S; Visseaux B; May L; Schrenzel J; Cattoir V
    Clin Microbiol Infect; 2021 Feb; 27(2):182-191. PubMed ID: 32120036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long and winding regulatory road for laboratory-developed tests.
    Weiss RL
    Am J Clin Pathol; 2012 Jul; 138(1):20-6. PubMed ID: 22706853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Medical devices containing materials derived from animal sources (except for in vitro diagnostic devices), guidance for FDA reviewers and industry; availability--FDA. Notice.
    Fed Regist; 1998 Nov; 63(215):60009-10. PubMed ID: 10187389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolomic Laboratory-Developed Tests: Current Status and Perspectives.
    Lichtenberg S; Trifonova OP; Maslov DL; Balashova EE; Lokhov PG
    Metabolites; 2021 Jun; 11(7):. PubMed ID: 34206934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.